Literature DB >> 22370724

MTHFR polymorphism and the risk of prostate cancer: a meta-analysis of case-control studies.

X-L Li1, J-H Xu.   

Abstract

BACKGROUND: 5,10-Methylenetetrahydrofolate reductase (MTHFR) polymorphisms implicated in the cancer development, but the published studies had yielded inconsistent results.
METHODS: Pubmed was searched for all published case-control studies about MTHFR polymorphisms and prostate cancer risk.
RESULTS: In all, 13 studies including 5872 cases and 6255 controls described C677T genotypes, among which 9 articles, containing 2847 cases and 3657 controls described A1298C genotypes, were involved in our meta-analysis. Odds ratios (ORs) with 95% confidence intervals (CIs) were estimated to assess the association between MTHFR polymorphisms and prostate cancer risk, heterogeneity, publication bias and sensitivity were also calculated. Overall, meta-analysis indicated that the 677T allele was more likely to exert protective effect on prostate cancer risk (random-effects pooled OR, 0.78 (0.64-0.96); P=0.016 (P=0.033 for heterogeneity studies)) in a recessive genetic model, no associations were found in other genetic models or in comparing a/a versus A/A homozygous. Neither did we find any difference in effects on high or low aggressive prostate cancer. No evidence of an association of MTHFR A1298C polymorphism with prostate cancer was found.
CONCLUSIONS: C677T of the MTHFR gene may provide protective effects on susceptibility to prostate cancer risk.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22370724     DOI: 10.1038/pcan.2012.5

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN: 1365-7852            Impact factor:   5.554


  3 in total

Review 1.  Second primary malignancies in multiple myeloma: A review.

Authors:  Christina Poh; Theresa Keegan; Aaron Seth Rosenberg
Journal:  Blood Rev       Date:  2020-09-06       Impact factor: 8.250

2.  Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics.

Authors:  P Razavi; K A Rand; W Cozen; A Chanan-Khan; S Usmani; S Ailawadhi
Journal:  Blood Cancer J       Date:  2013-06-28       Impact factor: 11.037

3.  Methylenetetrahydrofolate reductase (MTHFR) polymorphisms and promoter methylation in cervical oncogenic lesions and cancer.

Authors:  Anca Botezatu; Demetra Socolov; Iulia V Iancu; Irina Huica; Adriana Plesa; Carmen Ungureanu; Gabriela Anton
Journal:  J Cell Mol Med       Date:  2013-02-28       Impact factor: 5.310

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.